A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.

Trial Details

NCT ID
NCT06926283
Phase
PHASE1
Sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • DXC008
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Those who voluntarily sign the ICF and follow the protocol requirements.
  • Male or female.
  • Age: ≥ 18 years and ≤ 75 years.
  • Expected life expectancy ≥ 6 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →